IDGC - PLEASE HELP

New Post Public Reply Private Reply Replies (0) Message Board
guidelines
473
IDGC - PLEASE HELP

Question: Can anyone share thoughts on whether I should stay in (50mil @ .0001) or get out while there is volume trading? (today traded 1.2bil all @.0001s)

I ask because IDGC has not been above $.0001 (legitimately) - someone paint-jobbed the two year and six month chart to apparently deceive chart reviewers into believing that the stock actually .002 and .001 two or three times over months, but actually, it did not. They spenta couple hundred dollars to create an appearance of a brief run up a couple points - but I discovered only 1 to 2mil shares traded on each paintjob run). That said, the CEO somehow got OTC to show the stock current today via an "attorney letter" paint job! Crazy OTC market, ehh?

Main Question: I do not want to miss a "lotto" chance that the stock may be able to do what it has not done in 3 years - climb above .0001 - so your insight would be greatly appreciated. If you guys are just too busy, please don't worry about spending alot of time on this quandry. :-)
Question: Is this one of those companies that feed market makers who trade fractions of .0001s (.00005) and eek out some marginal profits selling to suckers like me @ .0001?

Question: can anyone of the team here translate what the below poster is trying to imply as far as immediate value added to IDGC PPS by the "level 1 asset of a few million shares of PUYY? (PUYY trades @ $0.60 PPS)


Post by Pistol Pete feb 10, 2017: - can anyone translate what realistic immediate $value he is implying here?

"MUST READ IDGC SHAREHOLDERS

WE Thought we owned 1 MILLION SHARES OF PYHH
TURNS OUT WE OWN 1 MILLION + 8 MILLION MORE = 9 MILLION TOTAL

PYHH 9 million shares x $0.71 = $6.4 million divided by 5.7 billion shares total = $0.0011 PER SHARE IDGC SHOULD BE TRADING AT

? INVESTMENT HOLDINGS

https://www.otcmarkets.com/ajax/showFinancial...?id=165696

The Company owns 1,000,000 shares of common stock in PYHH. This constitutes a
Level I asset because there are quoted prices for the stock in an active market, and is therefore
valued at $0.15 per share, the market price on the balance sheet date. The company has
recently hired Kyle Charles Young Attorney out of Palm Beach, Florida to assist the company in
deciding a course of action regarding the deposit and sale of the PYHH Shares. These shares
were acquired as compensation from a consulting agreement with PYHH in 5/2013, the
company and Transfer Agent has blocked the legend removal from the certificate and neither
has given a valid legal argument for their actions.
The Company owns 198,385 shares of Series B Convertible Preferred Stock in PHYH. Each
share can be converted into 40 shares of common stock, a total of 7,935,400 common
shares if they were all converted. This constitutes a Level III asset because there are no current
quoted prices for the identical common stock in an active market, and is therefore valued at $0
per common share equivalent, the market price of the common stock on the balance sheet date.
The Company owns 500,000 shares of common stock in Jack Rockwell, Inc. This constitutes a
Level 3 asset because it is a startup private company in which there is no reliable way
to determine the fair market value. The Company invested $25,000 during the three
months ended December 31, 2016 and no fair value adjustments have been made.
The company also has two issued patents with the USPTO and has one IP Valuation on one of
the issued patents valued in excess of $5 million dollars US. The valuation report will be
released with these Q2 Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

MAMMOTION's Bold Leap in Robotic Lawn Care at IFA 2026

Updated Category News Views 3

MAMMOTION Makes Waves with New Robotic Mowers Gather 'round, folks, because MAMMOTION's making some noise over at IFA 2026 in Berlin. If you've been stuck battling the wild edges of your lawn with a rusty old mower, MAMMOTION might just have the tech to save your weekends—and some grass along the way. This ain't no shiny gadget; it’s a full-on upgrade to lawn war...

Continue Reading
Holland America Evolution: Revamping Luxury at Sea

Updated Category News Views 3

Setting Sail on a Fresh Wave of Luxury It's a whole new world aboard the Oosterdam, folks. Holland America's making waves with the debut of a reimagined Ocean Bar that promises to inject a healthy dose of glamour back into cruising. Forget the stuffy maritime tales of yesteryear; this isn't just a facelift—it's a full-blown Renaissance at sea. A nod to the golden age of...

Continue Reading
Beyoncé Drops Remastered 'B'DAY'; Celebrates Legacy

Updated Category News Views 2

Every so often, an artist comes around who's not just making music but shifting the very landscape of their genre. Beyoncé isn't just marking her birthday today; she's reminding the world of a career-defining moment with the release of her remastered deluxe version of 'B'DAY'. This isn't just a stroll down memory lane; it's a full-blown revival of an era that reshaped...

Continue Reading
Eosera Defies Odds with Texas-Made Ear Care Dominance

Updated Category News Views 3

Who would've thought an ear care outfit outta Fort Worth could snag a spot on the Inc. 5000 list for six years running? That's right, eosera® is hanging tough, even while the industry's been in a tailspin and tariffs have been squeezing everyone’s margins. Pushing Through Tough Terrain The ear care sector isn't exactly the first place investors look for a splash,...

Continue Reading
Aardvark Therapeutics Faces Investor Lawsuit for Fraud

Updated Category News Views 1

Investors' Trust on Shaky Grounds There it is, staring right back at investors: a securities fraud class action lawsuit against Aardvark Therapeutics. Not exactly the news a shareholder wants to digest over breakfast. If you’ve got skin in the game with Aardvark Therapeutics (NASDAQ: AARD), you might wanna keep reading. Hagens Berman Sobol Shapiro LLP, a name that's no...

Continue Reading
Hamamatsu & AIxMed to Automate Cytology Workflows

Updated Category News Views 2

Why This Collaboration Matters Here comes an interesting tidbit from the world of cytology: Hamamatsu and AIxMed are banding together to tackle workflow inefficiencies. Picture this—two powerhouses coming together to create a tool that might just relieve lab technicians from the tedious task of manually checking cytology slides. In a world where efficiency is king, this...

Continue Reading
Aristocrat's Tiki Fire Slots Heat Up North America

Updated Category News Views 0

The Polynesian Flame Ignites: Tiki Fire Hits Online Games Just when you thought the iGaming world was catching its breath, Aristocrat Interactive throws another curveball. The buzz around their Lightning Link™ series, especially the launch of High Stakes™ in July, took the scene by storm. Now, just in time for another sizzle, they've rolled out Tiki Fire™, bringing...

Continue Reading
USSM and IonicRE Partner to Enhance US Rare Earths Supply

Updated Category News Views 1

Sometimes, it's not just about playing the game, but knowing which card to play. US Strategic Metals (USSM) and Ionic Rare Earths USA just unveiled a strategic move that’s likely to shake things up in the wild world of rare earths. As the partnership gears up to build a magnet recycling facility in Missouri, there’s chatter around creating a sustainable supply chain...

Continue Reading
Wise Group Investors Alert Ahead of Key Legal Deadline

Updated Category News Views 0

Sizing Up the Legal Stakes for Wise Group Alright, here's a doozy that's bound to get your attention if you've got a stake in Wise Group plc (NASDAQ: WSE). We're talking about a looming securities class action, with the deadline to get involved barreling down like a runaway freight train. Before September 29, 2026, to be exact—mark it, circle it, do whatever you have to...

Continue Reading
Curaleaf Eyes Growth: Conference Signals Opportunities

Updated Category News Views 1

Curaleaf's Strategic Move: Getting in Front of Investors Here comes Curaleaf Holdings, stepping into the spotlight with their eye on increasing investor engagement. Announcing their participation in the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference, the folks at Curaleaf aren't just talking—they're putting their top brass under the lights. You...

Continue Reading

Top 5 Most Recently Viewed Articles

Beazer Homes Boosts Share Repurchase Campaign Amid Market Changes

Updated Category News Views 95

Beazer Homes Increases Share Repurchase Initiative Beazer Homes USA, Inc. (NYSE: BZH) has recently communicated a significant acceleration in its share repurchase activity, a move prompted by fluctuations in its share price. The company has approximately $24.8 million remaining under its authorized share repurchase program. This decision illustrates Beazer's commitment to...

Continue Reading
Takeda Shares Groundbreaking Findings on Narcolepsy Treatment

Updated Category News Views 94

Groundbreaking Narcolepsy Treatment Insights by Takeda In a major development for those living with narcolepsy, Takeda will share important findings about its innovative drug, TAK-861, at Sleep Europe 2024. This conference is a key moment for Takeda to highlight progress in both understanding and treating this complex condition. Narcolepsy typically presents as...

Continue Reading
Celebrate Presidents Day with the U.S. Postal Service Updates

Updated Category News Views 151

Understanding Presidents Day Observance by the U.S. Postal Service The U.S. Postal Service (USPS) recognizes Presidents Day as a holiday, meaning that all Post Office locations will be closed, providing a day of rest for employees while encouraging customers to utilize self-service options. This aligns with the USPS commitment to serving communities effectively. Accessing...

Continue Reading
Sidetrade Celebrates Major Milestone in Euronext Tech Leaders

Updated Category News Views 180

Sidetrade's Prominent Inclusion in Euronext's Tech Leaders Sidetrade, a frontrunner in AI-driven Order-to-Cash applications, recently announced its inclusion in the prestigious Euronext Tech Leaders Index, a pan-European initiative that highlights the continent’s most innovative and rapidly growing tech companies. This initiative, launched in 2022 by Euronext,...

Continue Reading
Cue Biopharma Sees Promising Growth in Recent Financial Review

Updated Category News Views 125

Cue Biopharma's Financial Highlights and Strategic Changes BOSTON — Cue Biopharma, Inc. (NASDAQ: CUE), a trailblazer in the biopharmaceutical sector, is focused on revolutionizing immunotherapy through its innovative therapies. The company has reported substantial progress in its fourth quarter and full year 2024 financial results, underscoring its commitment to...

Continue Reading